Pub Date : 2025-11-19DOI: 10.1016/j.jvir.2025.107920
Didier Jourdain BS
Cybersecurity threats to medical imaging systems and workflows are no longer confined to information technology departments; they directly affect interventional radiology (IR) practice, patient safety, and procedural continuity. Two thirds of healthcare organizations experienced ransomware in 2024, with median and mean ransom payments of 1.5 million and 4.4 million dollars, respectively, and 725 large breaches of protected health information were reported in the United States that year. Such incidents increasingly disrupt IR workflows, delay emergent and elective procedures, force patient diversion, and create downstream clinical risks. This review synthesizes data from national reports, peer-reviewed literature, and real-world case examples to highlight high-priority threats including ransomware, credential compromise, vendor and supply chain exposures, insecure Internet of Medical Things devices, and vulnerabilities associated with artificial intelligence tools and aligns them with practical mitigation strategies grounded in the National Institute of Standards and Technology Cybersecurity Framework. By engaging directly in cybersecurity governance, risk assessment, and downtime planning, IR physicians can help ensure resilient imaging infrastructure and safe adoption of emerging technologies, safeguarding patient care when it matters most.
{"title":"Cybersecurity for Interventional Radiologists: A Clinical Imperative for Protecting Patient Data and Imaging Systems","authors":"Didier Jourdain BS","doi":"10.1016/j.jvir.2025.107920","DOIUrl":"10.1016/j.jvir.2025.107920","url":null,"abstract":"<div><div>Cybersecurity threats to medical imaging systems and workflows are no longer confined to information technology departments; they directly affect interventional radiology (IR) practice, patient safety, and procedural continuity. Two thirds of healthcare organizations experienced ransomware in 2024, with median and mean ransom payments of 1.5 million and 4.4 million dollars, respectively, and 725 large breaches of protected health information were reported in the United States that year. Such incidents increasingly disrupt IR workflows, delay emergent and elective procedures, force patient diversion, and create downstream clinical risks. This review synthesizes data from national reports, peer-reviewed literature, and real-world case examples to highlight high-priority threats including ransomware, credential compromise, vendor and supply chain exposures, insecure Internet of Medical Things devices, and vulnerabilities associated with artificial intelligence tools and aligns them with practical mitigation strategies grounded in the National Institute of Standards and Technology Cybersecurity Framework. By engaging directly in cybersecurity governance, risk assessment, and downtime planning, IR physicians can help ensure resilient imaging infrastructure and safe adoption of emerging technologies, safeguarding patient care when it matters most.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 3","pages":"Article 107920"},"PeriodicalIF":2.6,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145574827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-19DOI: 10.1016/j.jvir.2025.107919
Pooja Sai Muddana MD, Sheetal Sharma MD, Jineesh Valakkada MD, Ajay Alex DM, Anoop Ayyappan MD
{"title":"Endovascular Aortic Repair (EVAR) within Endovascular Aortic Repair (EVAR): Bifurcated Graft Relining for Type III Endoleak with Aortocaval Fistula","authors":"Pooja Sai Muddana MD, Sheetal Sharma MD, Jineesh Valakkada MD, Ajay Alex DM, Anoop Ayyappan MD","doi":"10.1016/j.jvir.2025.107919","DOIUrl":"10.1016/j.jvir.2025.107919","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 2","pages":"Article 107919"},"PeriodicalIF":2.6,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To review the safety and effectiveness of carotid artery stent placement (CAS) in treating symptomatic carotid web (CW) and preventing stroke recurrence.
Materials and Methods
All adult patients with CW with ipsilateral stroke in this institution from January 2020 to March 2025 were reviewed for demographics, comorbidities, presentation, anatomy, treatment characteristics, hospital course, and 6-month outcomes with recurrence stroke and modified Rankin Scale (mRS) score.
Results
Twelve patients with CW and anterior circulation stroke with a mean age of 45 years (SD ± 12) were included. Ten (83%) patients were female, 2 (17%) were diagnosed with hypercoagulable states, and none had atrial fibrillation. Ten patients (83%) experienced large vessel occlusion (LVO). Eight patients (67%) underwent treatment of CW with CAS, and 4 (33%) had no endovascular treatments. The mean time from LVO thrombectomy to CAS treatment of CW was 5 days. No immediate CAS complications were noted, and none of the patients treated with CAS experienced stroke recurrence within 6-month follow-up (all had mRS scores of <2). Four patients (33%) experienced poor outcomes (mRS score, >2) from recurrent strokes, all (100%) of whom never had their CW treated.
Conclusions
Same hospitalization treatment of CW with CAS after stroke is safe and effective in preventing stroke recurrence. Patients appear to be at high risk for multiple recurrent strokes if not treated within the first 6 months.
{"title":"Endovascular Stent Placement in Patients with Symptomatic Carotid Web Is Considered a Safe and Effective Step to Prevent Stroke Recurrence","authors":"Faraz Behzadi MD , Neehar Gaddam DO, MPH , Judy Dawod MD , Savdeep Singh MD , Nikhil K. Mehta MD","doi":"10.1016/j.jvir.2025.107921","DOIUrl":"10.1016/j.jvir.2025.107921","url":null,"abstract":"<div><h3>Purpose</h3><div>To review the safety and effectiveness of carotid artery stent placement (CAS) in treating symptomatic carotid web (CW) and preventing stroke recurrence.</div></div><div><h3>Materials and Methods</h3><div>All adult patients with CW with ipsilateral stroke in this institution from January 2020 to March 2025 were reviewed for demographics, comorbidities, presentation, anatomy, treatment characteristics, hospital course, and 6-month outcomes with recurrence stroke and modified Rankin Scale (mRS) score.</div></div><div><h3>Results</h3><div>Twelve patients with CW and anterior circulation stroke with a mean age of 45 years (SD ± 12) were included. Ten (83%) patients were female, 2 (17%) were diagnosed with hypercoagulable states, and none had atrial fibrillation. Ten patients (83%) experienced large vessel occlusion (LVO). Eight patients (67%) underwent treatment of CW with CAS, and 4 (33%) had no endovascular treatments. The mean time from LVO thrombectomy to CAS treatment of CW was 5 days. No immediate CAS complications were noted, and none of the patients treated with CAS experienced stroke recurrence within 6-month follow-up (all had mRS scores of <2). Four patients (33%) experienced poor outcomes (mRS score, >2) from recurrent strokes, all (100%) of whom never had their CW treated.</div></div><div><h3>Conclusions</h3><div>Same hospitalization treatment of CW with CAS after stroke is safe and effective in preventing stroke recurrence. Patients appear to be at high risk for multiple recurrent strokes if not treated within the first 6 months.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 2","pages":"Article 107921"},"PeriodicalIF":2.6,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145574845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14DOI: 10.1016/j.jvir.2025.107918
Wei Luo, Qikun Guo, Weijie Luo, Menglan Chu, Yang Su, Xuexian Zhang, Jinmiao Chen, Shangbo Shi, Bin Xiong
Purpose: To evaluate the characteristics and effectiveness of embolization for hemoptysis due to pulmonary aspergillosis and analyze the risk factors for recurrence.
Materials and methods: This retrospective cohort study evaluated 158 consecutive patients, including 117 males and 41 females with a median age of 60 years (range,18-84 years), who underwent transarterial embolization (TAE) for aspergillosis-related hemoptysis. The rate of absence of recurrent hemoptysis was calculated via Kaplan-Meier analysis, with univariate and multivariate Cox regression to analyze the risk factors for recurrence.
Results: Among patients with aspergillosis-related hemoptysis in this cohort, 77% had comorbid bronchiectasis. TAE achieved a 93% clinical success rate, with postprocedural chest pain and fever constituting the predominant adverse events. The rates of absence of recurrent hemoptysis at 1, 3, 6, 12, 24, and 36 months after TAE were 93%, 82%, 77%, 69%, 58%, and 57%, respectively. Multivariate Cox analysis identified pulmonary cavities (P = .006), bronchiectasis (P = .027), and embolization-required inferior phrenic artery (IPA) (P = .026) as independent predictors of recurrence.
Conclusions: TAE is safe and effective in treating aspergillosis-related hemoptysis. IPA that required embolization independently predicted recurrence of hemoptysis, and nonvascular predictors of recurrent hemoptysis were pulmonary cavity and bronchiectasis.
{"title":"Embolization for Hemoptysis in Pulmonary Aspergillosis: Effectiveness and Risk Factors for Recurrence.","authors":"Wei Luo, Qikun Guo, Weijie Luo, Menglan Chu, Yang Su, Xuexian Zhang, Jinmiao Chen, Shangbo Shi, Bin Xiong","doi":"10.1016/j.jvir.2025.107918","DOIUrl":"10.1016/j.jvir.2025.107918","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the characteristics and effectiveness of embolization for hemoptysis due to pulmonary aspergillosis and analyze the risk factors for recurrence.</p><p><strong>Materials and methods: </strong>This retrospective cohort study evaluated 158 consecutive patients, including 117 males and 41 females with a median age of 60 years (range,18-84 years), who underwent transarterial embolization (TAE) for aspergillosis-related hemoptysis. The rate of absence of recurrent hemoptysis was calculated via Kaplan-Meier analysis, with univariate and multivariate Cox regression to analyze the risk factors for recurrence.</p><p><strong>Results: </strong>Among patients with aspergillosis-related hemoptysis in this cohort, 77% had comorbid bronchiectasis. TAE achieved a 93% clinical success rate, with postprocedural chest pain and fever constituting the predominant adverse events. The rates of absence of recurrent hemoptysis at 1, 3, 6, 12, 24, and 36 months after TAE were 93%, 82%, 77%, 69%, 58%, and 57%, respectively. Multivariate Cox analysis identified pulmonary cavities (P = .006), bronchiectasis (P = .027), and embolization-required inferior phrenic artery (IPA) (P = .026) as independent predictors of recurrence.</p><p><strong>Conclusions: </strong>TAE is safe and effective in treating aspergillosis-related hemoptysis. IPA that required embolization independently predicted recurrence of hemoptysis, and nonvascular predictors of recurrent hemoptysis were pulmonary cavity and bronchiectasis.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"107918"},"PeriodicalIF":2.6,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145534064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-11DOI: 10.1016/j.jvir.2025.107915
Francesca Heiberg-Gibbons MBChB, BMedSci , Rushabh Shah BSc, MBChB, FRCR, EBIR , Ning Ngah MBChB, FRCR , Jacob Ibbetson MBChB , Simon P.G. Padley BSc, MBBS, MRCP, FRCR , Emily C. Bartlett MBBS, FRCR, PhD , Carole A. Ridge MB BCh BAO, MRCPI, FFRRCSI
{"title":"Joint Decision-Making in IR: A Retrospective Analysis of the Use of Audiovisual Patient Educational Tools for Patient Anxiety and Understanding","authors":"Francesca Heiberg-Gibbons MBChB, BMedSci , Rushabh Shah BSc, MBChB, FRCR, EBIR , Ning Ngah MBChB, FRCR , Jacob Ibbetson MBChB , Simon P.G. Padley BSc, MBBS, MRCP, FRCR , Emily C. Bartlett MBBS, FRCR, PhD , Carole A. Ridge MB BCh BAO, MRCPI, FFRRCSI","doi":"10.1016/j.jvir.2025.107915","DOIUrl":"10.1016/j.jvir.2025.107915","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 3","pages":"Article 107915"},"PeriodicalIF":2.6,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-07DOI: 10.1016/j.jvir.2025.107912
Domenico Mirabella, Salvatore Bruno, Manfredi La Marca, Ettore Dinoto, Carlo Setacci, Felice Pecoraro
Purpose: This study aims to assess the effectiveness of nitinol-constrained balloon (NCB; Chocolate, Medtronic) percutaneous transluminal angioplasty (PTA) for treating DISFORM III post-angioplasty dissections in chronic total occlusions (CTO) of the femoro-popliteal segment.
Materials and methods: The CHOCO-STAB study was conducted from February 2019 to February 2022. It included patients with peripheral artery disease (PAD) affected by chronic limb-threatening ischemia (CLTI). This study specifically included patients with DISFORM III post-angioplasty dissections who were treated using NCB angioplasty after initial PTA. The main outcomes assessed in this study were technical success and the occurrence of major adverse events (MAE).
Results: This study included 68 patients with a mean age of 72 years (SD: 10), of whom 39% were diabetic. The initially treated CTOs had a mean length of 10.32 mm (IQR: 5-15; SD: 5), with moderate or severe calcification in 28%. Forty-seven (69%) patients received initial treatment with drug-coated balloons (DCB). NCB angioplasty was feasible in all patients, achieving technical success in 62 (91%). Stent placement was required in the remaining 6 (9%) cases. Three-year estimated overall survival was 98.5%, primary patency was 88.2%, freedom from major amputation was 94.1%, and freedom from clinical TLR was 94.1%.
Conclusions: Post-angioplasty dissections represent a relevant adverse event that necessitates scaffolding in moderate and severe grades. The CHOCO-STAB study demonstrated the safety and potential of NCB angioplasty to reduce stent placement in patients treated with DCB and POBA who present post-angioplasty dissections.
{"title":"Effectiveness of Nitinol-Constrained-Balloon Angioplasty for Treating Post-Angioplasty Dissections in Chronic Total Occlusions of the Femoro-Popliteal Segment.","authors":"Domenico Mirabella, Salvatore Bruno, Manfredi La Marca, Ettore Dinoto, Carlo Setacci, Felice Pecoraro","doi":"10.1016/j.jvir.2025.107912","DOIUrl":"https://doi.org/10.1016/j.jvir.2025.107912","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to assess the effectiveness of nitinol-constrained balloon (NCB; Chocolate, Medtronic) percutaneous transluminal angioplasty (PTA) for treating DISFORM III post-angioplasty dissections in chronic total occlusions (CTO) of the femoro-popliteal segment.</p><p><strong>Materials and methods: </strong>The CHOCO-STAB study was conducted from February 2019 to February 2022. It included patients with peripheral artery disease (PAD) affected by chronic limb-threatening ischemia (CLTI). This study specifically included patients with DISFORM III post-angioplasty dissections who were treated using NCB angioplasty after initial PTA. The main outcomes assessed in this study were technical success and the occurrence of major adverse events (MAE).</p><p><strong>Results: </strong>This study included 68 patients with a mean age of 72 years (SD: 10), of whom 39% were diabetic. The initially treated CTOs had a mean length of 10.32 mm (IQR: 5-15; SD: 5), with moderate or severe calcification in 28%. Forty-seven (69%) patients received initial treatment with drug-coated balloons (DCB). NCB angioplasty was feasible in all patients, achieving technical success in 62 (91%). Stent placement was required in the remaining 6 (9%) cases. Three-year estimated overall survival was 98.5%, primary patency was 88.2%, freedom from major amputation was 94.1%, and freedom from clinical TLR was 94.1%.</p><p><strong>Conclusions: </strong>Post-angioplasty dissections represent a relevant adverse event that necessitates scaffolding in moderate and severe grades. The CHOCO-STAB study demonstrated the safety and potential of NCB angioplasty to reduce stent placement in patients treated with DCB and POBA who present post-angioplasty dissections.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"107912"},"PeriodicalIF":2.6,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145483531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-05DOI: 10.1016/j.jvir.2025.107908
Hooman Yarmohammadi, Sam Y Son, Aaron W P Maxwell, Ahmed S Elsakka, Vlasios S Sotirchos, Olivier Chevallier, Fuad Nurili, Fourat Ridouani, Etay Ziv, Joseph P Erinjeri, Ken Zhao, Christopher Cheleuitte-Nieves, Renata Mammone, Adam Michel, Christine A Iacobuzio-Donahue, Alice C Wei, Eileen M O'Reilly, Stephen B Solomon, F Edward Boas
Purpose: To evaluate the safety and feasibility of treating pancreatic tumors in an Oncopig tumor model, using bumetanide (BU)/ethiodized oil emulsion.
Materials and methods: Pancreatic tumors were induced in 18 transgenic Oncopigs with inducible p53 and Kras mutations. Sixteen pigs developed tumor and were treated with intra-arterial (IA) injection of BU/ethiodized oil emulsion (n = 6) (mean injected volume, 1.8 mL of 2.9 mL of ethiodized oil + 2.10 mL [0.44 mg, 0.02 mg/kg] of BU), IA injection of ethiodized oil (n = 3), and systemic intravenous gemcitabine (n = 2). Five pigs did not receive any treatment (control). Laboratory evaluation and contrast-enhanced computed tomography (CT) scan was obtained on Days 0, 7, and 14. Necropsy was performed on Day 14. Treatment was evaluated by tumor size change, radiographic response per Response Evaluation Criteria in Solid Tumors 1.1 at Day 14, and degree of tumor necrosis on histopathological examination. One-way analysis of variance and the Tukey-Kramer post hoc test were used.
Results: Median tumor diameter before treatment was 1.5 cm (interquartile range [IQR], 1.1-3.1 cm). No significant increase in the posttreatment serum lipase levels was detected in the BU/ethiodized oil group (P > .05). No clinical, radiographic, or histopathological evidence of pancreatitis was detected. Tumor size in the BU/ethiodized oil group decreased by a median of 10.3% (6.7%-13.6%, P < .05). The control group had an increase in median (IQR) tumor size by 45% (32.8%-61.4%, P < .05). The median tumor size change was significantly different between the BU/ethiodized oil and control groups (P = .01). Mean degree of necrosis was less than 10% in the treated groups (P > .05).
Conclusions: IA injection of BU/ethiodized oil emulsion is safe and feasible in treating pancreatic tumor in a transgenic porcine model.
{"title":"Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model.","authors":"Hooman Yarmohammadi, Sam Y Son, Aaron W P Maxwell, Ahmed S Elsakka, Vlasios S Sotirchos, Olivier Chevallier, Fuad Nurili, Fourat Ridouani, Etay Ziv, Joseph P Erinjeri, Ken Zhao, Christopher Cheleuitte-Nieves, Renata Mammone, Adam Michel, Christine A Iacobuzio-Donahue, Alice C Wei, Eileen M O'Reilly, Stephen B Solomon, F Edward Boas","doi":"10.1016/j.jvir.2025.107908","DOIUrl":"10.1016/j.jvir.2025.107908","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the safety and feasibility of treating pancreatic tumors in an Oncopig tumor model, using bumetanide (BU)/ethiodized oil emulsion.</p><p><strong>Materials and methods: </strong>Pancreatic tumors were induced in 18 transgenic Oncopigs with inducible p53 and Kras mutations. Sixteen pigs developed tumor and were treated with intra-arterial (IA) injection of BU/ethiodized oil emulsion (n = 6) (mean injected volume, 1.8 mL of 2.9 mL of ethiodized oil + 2.10 mL [0.44 mg, 0.02 mg/kg] of BU), IA injection of ethiodized oil (n = 3), and systemic intravenous gemcitabine (n = 2). Five pigs did not receive any treatment (control). Laboratory evaluation and contrast-enhanced computed tomography (CT) scan was obtained on Days 0, 7, and 14. Necropsy was performed on Day 14. Treatment was evaluated by tumor size change, radiographic response per Response Evaluation Criteria in Solid Tumors 1.1 at Day 14, and degree of tumor necrosis on histopathological examination. One-way analysis of variance and the Tukey-Kramer post hoc test were used.</p><p><strong>Results: </strong>Median tumor diameter before treatment was 1.5 cm (interquartile range [IQR], 1.1-3.1 cm). No significant increase in the posttreatment serum lipase levels was detected in the BU/ethiodized oil group (P > .05). No clinical, radiographic, or histopathological evidence of pancreatitis was detected. Tumor size in the BU/ethiodized oil group decreased by a median of 10.3% (6.7%-13.6%, P < .05). The control group had an increase in median (IQR) tumor size by 45% (32.8%-61.4%, P < .05). The median tumor size change was significantly different between the BU/ethiodized oil and control groups (P = .01). Mean degree of necrosis was less than 10% in the treated groups (P > .05).</p><p><strong>Conclusions: </strong>IA injection of BU/ethiodized oil emulsion is safe and feasible in treating pancreatic tumor in a transgenic porcine model.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"107908"},"PeriodicalIF":2.6,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145472423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this retrospective review, a head-mounted augmented reality (AR) display was investigated to evaluate its clinical usability and ergonomic benefits across multiple musculoskeletal image-guided procedures. Data were collected through an electronic survey with 5-point Likert scale (n = 9) and single-user motion analysis. Nine interventional radiologists rated their experience in procedures including drainage, biopsy, endovascular procedure, ablation, and cement augmentation. Kinematic data were obtained from 14 needle placement procedures (10 kyphoplasties and 4 spinal biopsies), comparing sessions with AR enabled (n = 7) versus without AR (n = 7). User feedback indicated high comfort (median Likert score, 5), ease of use (median Likert score, 4), and positive ergonomic impact (median Likert score, 5), with 66% reporting improved ergonomics. Motion analysis revealed procedures without AR required more frequent (P = .003) and greater magnitude (P = .0002) head turns during image-guided needle advancement. AR demonstrated improvements in ergonomic efficiency and user satisfaction for musculoskeletal interventional procedures, although image quality refinement could enhance clinical adoption.
{"title":"Augmented Reality Visualization in Musculoskeletal Interventions: User Feedback and Ergonomic Impact on Needle Placement Procedures","authors":"Afareen Jaleel MD , Ruben Geevarghese MD , Megan Worthington MD , Liwei Jiang MD , Jonathan Latzman MD , Debkumar Sarkar DO , Javin Schefflein MD , Francois H. Cornelis MD, PhD","doi":"10.1016/j.jvir.2025.107907","DOIUrl":"10.1016/j.jvir.2025.107907","url":null,"abstract":"<div><div>In this retrospective review, a head-mounted augmented reality (AR) display was investigated to evaluate its clinical usability and ergonomic benefits across multiple musculoskeletal image-guided procedures. Data were collected through an electronic survey with 5-point Likert scale (n = 9) and single-user motion analysis. Nine interventional radiologists rated their experience in procedures including drainage, biopsy, endovascular procedure, ablation, and cement augmentation. Kinematic data were obtained from 14 needle placement procedures (10 kyphoplasties and 4 spinal biopsies), comparing sessions with AR enabled (n = 7) versus without AR (n = 7). User feedback indicated high comfort (median Likert score, 5), ease of use (median Likert score, 4), and positive ergonomic impact (median Likert score, 5), with 66% reporting improved ergonomics. Motion analysis revealed procedures without AR required more frequent (<em>P</em> = .003) and greater magnitude (<em>P</em> = .0002) head turns during image-guided needle advancement. AR demonstrated improvements in ergonomic efficiency and user satisfaction for musculoskeletal interventional procedures, although image quality refinement could enhance clinical adoption.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 2","pages":"Article 107907"},"PeriodicalIF":2.6,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-04DOI: 10.1016/j.jvir.2025.107911
Thomas Williams MD , Alessandro Marquis MD , Pamela Unger MD , Christopher D. Yeisley MD , Cynthia J. Knauer RN, MS , Aaron M. Fischman MD , David N. Siegel MD , Ardeshir R. Rastinehad DO
Purpose
To develop a simple imaging-based scoring system, the prostate artery embolization (PAE)–glue penetration score (GPS; 0–6), for use in PAE with n-butyl cyanoacrylate (nBCA) and to examine how it relates to patient outcomes.
Materials and Methods
In a single-institution retrospective cohort of 49 men (July 2021 to May 2023), 2 blinded readers graded glue penetration per hemigland (0–3) and summed scores to a total PAE-GPS (0–6). The authors correlated GPS with International Prostate Symptom Score (IPSS), IPSS–quality of life (QoL), and Sexual Health Inventory for Men (SHIM) at 1, 6, and 12 months. The authors defined clinical success as achieving a ≥8-point or ≥25% reduction in IPSS plus a ≥1-point improvement in IPSS-QoL at any time point. The authors also analyzed outcomes by median lobe protrusion; adverse events were graded according to the Society of Interventional Radiology (SIR) adverse event criteria.
Results
The median follow-up was 258 days (interquartile range, 138–391 days). GPS distributions were 5–6 (61.2%), 3–4 (28.5%), and 0–2 (10.2%). Clinical success rates were 92.5%, 75%, and 80%, respectively. Significant improvements in IPSS and IPSS-QoL scores were observed at all follow-up intervals (P < .001). SHIM scores increased significantly at 12 months (P = .044). A direct correlation was observed between higher PAE-GPS and improved clinical outcomes, with no significant adverse events reported.
Conclusions
nBCA PAE shows midterm safety and effectiveness. PAE-GPS provides a visible and reproducible technical endpoint. Higher PAE-GPS grades were associated with greater improvements on univariate analysis.
{"title":"Glue (n-Butyl Cyanoacrylate) for Prostate Artery Embolization: Development of a Glue Penetration Score and Association with Clinical Outcomes","authors":"Thomas Williams MD , Alessandro Marquis MD , Pamela Unger MD , Christopher D. Yeisley MD , Cynthia J. Knauer RN, MS , Aaron M. Fischman MD , David N. Siegel MD , Ardeshir R. Rastinehad DO","doi":"10.1016/j.jvir.2025.107911","DOIUrl":"10.1016/j.jvir.2025.107911","url":null,"abstract":"<div><h3>Purpose</h3><div>To develop a simple imaging-based scoring system, the prostate artery embolization (PAE)–glue penetration score (GPS; 0–6), for use in PAE with <em>n</em>-butyl cyanoacrylate (<em>n</em>BCA) and to examine how it relates to patient outcomes.</div></div><div><h3>Materials and Methods</h3><div>In a single-institution retrospective cohort of 49 men (July 2021 to May 2023), 2 blinded readers graded glue penetration per hemigland (0–3) and summed scores to a total PAE-GPS (0–6). The authors correlated GPS with International Prostate Symptom Score (IPSS), IPSS–quality of life (QoL), and Sexual Health Inventory for Men (SHIM) at 1, 6, and 12 months. The authors defined clinical success as achieving a ≥8-point or ≥25% reduction in IPSS plus a ≥1-point improvement in IPSS-QoL at any time point. The authors also analyzed outcomes by median lobe protrusion; adverse events were graded according to the Society of Interventional Radiology (SIR) adverse event criteria.</div></div><div><h3>Results</h3><div>The median follow-up was 258 days (interquartile range, 138–391 days). GPS distributions were 5–6 (61.2%), 3–4 (28.5%), and 0–2 (10.2%). Clinical success rates were 92.5%, 75%, and 80%, respectively. Significant improvements in IPSS and IPSS-QoL scores were observed at all follow-up intervals (<em>P</em> < .001). SHIM scores increased significantly at 12 months (<em>P</em> = .044). A direct correlation was observed between higher PAE-GPS and improved clinical outcomes, with no significant adverse events reported.</div></div><div><h3>Conclusions</h3><div><em>n</em>BCA PAE shows midterm safety and effectiveness. PAE-GPS provides a visible and reproducible technical endpoint. Higher PAE-GPS grades were associated with greater improvements on univariate analysis.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 2","pages":"Article 107911"},"PeriodicalIF":2.6,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号